Dose Escalating Study of Foxy-5 in Breast-, Colon- or Prostate Cancer Patients

Inclusion Criteria

• •Males and females of at least 18 years of age
• •* Histologically/cytologically documented diagnosis of metastatic breast, colon or prostate cancer, refractory to standard therapy or for which no curative therapy exists
• •* Must have an evaluable tumour appropriate for biopsy as determined by the Investigator.
• •* Loss of or reduced Wnt-5a protein expression in primary or metastatic tumour cells, characterised by IHC analysis
• •* Eastern Cooperative Oncology Group (ECOG) performance status of \<= 1
• •* Life expectancy of at least 3 months
• •* Unresectable disease, i.e. the metastases cannot be surgically removed with a curative intent
• •* 4 weeks must have elapsed since the patient has received any other IMP
• •* 4 weeks must have elapsed since the patient has received any anti cancer treatment; including radiotherapy (except for single dose of palliative radiotherapy), cytotoxic chemotherapy, biologic agents or targeted therapy
• •* 2 weeks must have elapsed since any prior surgery or therapy with bone marrow stimulating factors
• •* Adequate haematological functions as defined by:
• •* Absolute neutrophil count \>= 1.5 10E9/L
• •* Platelets \>= 100 10E9/L
• •* Hemoglobin \>= 5.6 mmol/L
• •* Adequate hepatic function as defined by:
• •* Total bilirubin \<= 1.5 x the upper limit of normal (ULN)
• •* Aspartate aminotransferase (AST) \<= 2.5 x ULN\*
• •* Alanine aminotransferase (ALT) \<= 2.5 x ULN\*
• •* For patients with liver metastasis adequate hepatic function is defined by AST \<= 5 x ULN and ALT \<= 5 ULN.
• •* Adequate renal function as defined by Serum creatinine \<= 1,5 x ULN
• •* Patients in active anti-coagulating treatment must be evaluated according to local standards on the discretion of the Investigator..
• •* Provision of written informed consent
• •* Willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other study procedures
• •* Sexually active males and females of child-producing potential, must use adequate contraception (intrauterine devices, hormonal contraceptives (contraceptive pills, implants, transdermal patches, hormonal vaginal devices or injections with prolonged release) or diaphragm always with spermicidal jelly and a male condom) for the study duration and at least six months afterwards